Federal Circuit Flattens Bayer Patent on Erectile Dysfunction Drug
In a win for Goodwin Procter, a unanimous panel ruled Wednesday that a patent covering Bayer's Staxyn is obvious in light of numerous previous patent applications and medical journal articles. The decision reverses U.S. District Judge Gregory Sleet of Delaware.
November 01, 2017 at 06:14 PM
3 minute read
The original version of this story was published on Delaware Law Weekly
The U.S. Court of Appeals for the Federal Circuit has let the air out of a Bayer Pharma AG erectile dysfunction drug.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2How I Made Office Managing Partner: 'If You Are Aware of Areas for Improvement and You Can Play a Role in That, Speak Up,' Says Jennifer Mellott of Freshfields
- 3'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5Burns & Levinson to Wind Down After 64 Years in Boston
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
